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Visceral leishmaniasis (VL) is a lethal disease if left untreated. Current treatments produce variable rates of treatment failure and
toxicity without sterile cure, rendering treatment efficacy monitoring essential. To avoid repeated invasive tissue aspirates as well as
empirical treatment, there is a need for new tools that allow a less-invasive and early assessment of treatment efficacy in the field.
Cross-sectional studies have suggested levels of cytokines/chemokines after whole blood stimulation as good markers of cure, but
longitudinal studies are lacking. In this study, we followed 13 active VL cases in an endemic area in Ethiopia by measuring the
production of IFN-γ, TNF-α, IP-10, IL-2, IL-10, MCP-1, and MIG before, during, and at the end of treatment. After 24 hours of
stimulation of whole blood with soluble Leishmania antigen, we observed an early, robust, and incremental increase of IFN-γ,
TNF-α, and IP-10 levels in all patients during treatment. Moreover, based on the IFN-γ levels that showed an average 13-fold
increase from the time of diagnosis until the end of treatment, we could almost perfectly discriminate active from cured status.
Similar concentrations and patterns were found in stimulation assays with the two main Leishmania species. The levels of
IFN-γ, IP-10, or TNF-α also seemed to be inversely associated with the parasite load at baseline. Despite a 1/10 drop in
concentrations, similar patterns were observed in IFN-γ and IP-10 levels when dried plasma spots were stored at 4°C for
an average of 225 days. All the above evidence suggests a detectable restoration of cell-mediated immunity in VL and its
association with parasite clearance. With a potential application in rural settings by means of dried plasma spots, we
recommend to further explore the early diagnostic value of such assays for treatment efficacy monitoring in large cohort
studies including treatment failure cases.
1. Introduction
Visceral leishmaniasis (VL) is a neglected vector-borne
protozoan disease, prevalent in the tropics, subtropics,
and Mediterranean basin. It is responsible for an estimated
50,000-90,000 annual cases globally and lethal if left
untreated [1, 2]. Over 90% of the cases are concentrated
in Bangladesh, India, Brazil, Sudan, South Sudan, and
Ethiopia [2]. It is characterized by persistent low-grade
fever, weight loss, anemia, pancytopenia, hepatosplenome-
galy, edema, muscle wasting, diarrhea, and hypergamma-
globulinemia. Through time, it may cause bleeding due
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to thrombocytopenia which may progress to sepsis and
severe cachexia [3, 4]. The limited range of drugs currently
used for treatment includes pentavalent antimonials,
pentamidine, amphotericin B deoxycholate and its lipid
formulations, miltefosine, and paromomycin. However, they
all produce considerable but variable rates of treatment
failure (10-59%) and sterile cure is almost never achieved
[5–10]. Due to the latter, the World Health Organization
(WHO) defines “true cure” as a patient with no relapse
episode in 3-6 months after treatment stop. In addition, the
treatments are lengthy, have a high toxicity with regular side
effects, and are often expensive [11]. Taken together, the need
to monitor drug efficacy is paramount.
Considering the lack of comparable alternatives, WHO
recommends a splenic, bone marrow or lymph node aspirate
as a test for diagnosis but also as a test of cure [12]. Neverthe-
less, patients are often discharged purely following improve-
ment of clinical signs in more rural settings, due to the need
of an experienced health worker to perform the procedure or
bleeding risk. To avoid repeated invasive tissue aspirates as
well as empirical treatment, there is a need for quick, easy-
to-use, and sensitive tools that allow a less-invasive assess-
ment of treatment efficacy. Such tools could aid clinicians
in making decisions about the continuation or change of
treatment regimens. Moreover, markers able to identify the
initiation of a successful treatment might help to shorten
the treatment duration.
Serological techniques cannot be used for this purpose as
antibodies remain high for several years. Molecular tech-
niques seem promising, but could be less suitable as the
parasitic load mostly decreases steeply after two days of treat-
ment and gives no information on the host’s immunological
recovery [13–15]. Following the latter, one of the key immu-
nological characteristics of active disease is a profound
immunosuppression and impaired production of inter-
feron-γ (IFN-γ) and associated cytokines. Activation of
infected macrophages by IFN-γ triggers the production of
nitric oxide synthases/reactive oxygen species (NOS/ROS)
that facilitates parasite killing, indicating the importance of
cellular sources of IFN-γ [16, 17]. The host’s Leishmania-
specific cell-mediated immunity is thus a key determinant
in resistance and clearance of a Leishmania infection and
could serve as a proxy measurement of the host’s capacity
to maintain future recrudescence or to resist reinfections of
Leishmania as it is known to last for several years [18]. There-
fore, techniques such as the whole blood stimulation assay
(WBA) which measures the in vitro cell-mediated immune
response after stimulation with soluble Leishmania antigens
have been proposed to monitor disease recovery [19, 20].
Recent findings in cross-sectional studies of Ethiopia, Spain,
and Bangladesh further enforced the idea that gradual
increases in IFN-γ or in IFN-γ-induced protein 10 (IP-10
or CXCL10), monokine induced by IFN-γ (MIG or CXCL9),
tumor necrosis factor-alpha (TNF-α), and monocyte che-
moattractant protein 1 (MCP-1 or CCL2) levels in soluble
Leishmania antigen- (SLA-) stimulated whole blood could
indicate that treatment has been successful and could be
targeted as biomarkers of clinical cure in VL [20–23].
The search for a robust marker is still ongoing, as different
cytokines and chemokines have been proposed, but vary
by geographical area, Leishmania strain, and outcome
identification (asymptomatic, active, cured). To date, this
assay has never been evaluated longitudinally to monitor
individual L. donovani-infected patients during the course
of treatment. And only one cross-sectional study reported
on its value in the East African L. donovani setting, which
was restricted to the IFN-γ and interleukin- (IL-) 10 ana-
lytes. In remote regions, a simpler storage and transporta-
tion method would be highly needed. Protein Saver 903
cards have shown potential as an alternative method for
transporting SLA-stimulated plasma samples, even at
ambient temperature, for the later analysis of IL-2, IFN-γ,
IP-10, MIG, and MCP-1 concentrations [24].
The main aim of this pilot study was to further vali-
date the usefulness of this assay as a treatment efficacy
monitoring tool in Ethiopian VL patients by means of a
first-in-its-kind longitudinal evaluation of individual patients
during the course of treatment. To further fine-tune the
development and implementation of a WBA in research
and clinical activities among VL patients in East Africa, we
also assessed strain specificity, a more field-adapted method,
and demonstrated the value of seven previously proposed
cytokine/chemokine markers.
2. Materials and Methods
2.1. Study Design. An institutional-based cohort study was
conducted from March to September 2018 in which a total
of 21 VL patients were recruited at time of diagnosis (referred
to as day zero (D0)). A 2ml venous blood sample was
collected in a lithium-heparin tube at D0, after the first week
of the treatment (W1), and at end of treatment (EOT). Socio-
demographic data was collected by questionnaire and clinical
data was collected from the patient’s medical record by using
a case report format. One patient died during treatment
because he suffered from acute kidney injury and anemia.
In addition, three were lost to follow-up during treatment
and four had a missing time point. Therefore, a total of 13
VL patients with complete follow-up during treatment was
included in the main analyses. A total of 19 VL patients were
used for baseline analyses.
The study protocol was reviewed and approved by the
research ethics committee of the School of Biomedical and
Laboratory Sciences, College of Medicine and Health
Sciences, University of Gondar, and the Institutional Review
Board of the Institute of Tropical Medicine. All study
participants provided informed consent.
2.2. Study Population. Patients were recruited and followed
at the Leishmaniasis Research and Treatment Centre
(LRTC) at the University of Gondar, Ethiopia. The center
is located in the northwestern part of Ethiopia close to the
high VL-endemic areas along the border with Sudan. Only
microscopically confirmed VL cases (by the spleen or bone
marrow aspiration) were included in the study. Patients with
a concurrent medical emergency (unconscious and severely
ill individuals), documented coinfection (tuberculosis (TB),
human immunodeficiency virus (HIV), and helminthic
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infection), records of any immune suppressive drugs, or who
were younger than 18 or older than 65 years were considered
noneligible.
2.3. Operational Definitions. Body mass index (BMI) was
defined as the weight in kilograms divided by the square of
the height in meters (kg/m2), and the following criteria were
used: underweight (BMI < 18:5 kg/m2) and normal or healthy
weight (BMI within the range of 18.5-25 kg/m2) [25]. Fever
was considered if the body temperature was above 37°C.
Cure from leishmaniasis was defined at clinical discharge
based on the absence of clinical signs or if a repeated splenic
or bone marrow aspirate was taken, negative microscopy at
end of treatment [26]. Following WHO guidelines, seven of
the 13 VL patients (54%) confirmed “true cure” status at six
months after therapy and six patients were lost to follow-up.
After splenic/bone marrow aspiration, parasites were
detected with standard Giemsa staining. The parasite density
score was determined using a logarithmic scale ranging from
0 (no parasites per 1000 oil immersion fields), 1+ (1–10
parasites per 1000 fields), 2+ (1–10 parasites per 100 fields),
3+ (1–10 parasites per 10 fields), 4+ (1–10 parasites per field),
5+ (10–100 parasites per field) to +6 (>100 parasites per
field) [27].
2.4. Preparation of Soluble Leishmania Antigen (SLA). L.
donovani and L. infantum antigens were prepared from
promastigote cultures in the stationary phase (S-698 strain
MHOM/ET/67/HU3 and JPC strain MCAN/ES/98/LLM-
722, respectively) as previously described [28, 29]. The
parasites were first washed with 1X phosphate-buffered
saline (PBS) and centrifuged at 1000 g for 20min at 4°C.
The supernatant was discarded, and the pellet resuspended
in lysis buffer (50mM Tris/5mM EDTA/HCl, pH 7). These
samples were subjected to three cycles of freezing/thawing
and then sonicated three times (40W for 20 s) before being
centrifuged again at 27,000 g for 20min at 4°C. The superna-
tants were collected and centrifuged at 100,000 g for 4 hours
at 4°C, to remove the membrane antigens. Finally, the super-
natants were divided into aliquots and stored at -80°C until
use. The protein content was quantified following the
bicinchoninic acid method (BCA), using the Pierce BCA Pro-
tein Assay Kit (Bio-Rad, USA).
2.5. Whole Blood Stimulation Assay (WBA). Whole blood
samples were stimulated as previously described [20]. Briefly,
for each sample, an aliquot of 500μl blood was transferred in
a control tube (unstimulated), two tubes containing 10μg/ml
SLA from L. donovani and 10 μg/ml SLA from L. infantum,
and a positive control tube with phytohemagglutinin
(PHA). The latter and SLA of both species were lyophilized
for utility and preservation in the field. Next, all of tubes were
incubated at 37°C for 24h. After incubation time, the super-
natants were collected and stored at -80°C until cytokine/-
chemokine determination.
2.6. Storage of Stimulated Plasma Samples in Filter Paper. In
parallel with freezing down stimulated plasma, 40μl was
dropped onto two premarked 1.2 cm diameter circles on sep-
arate Protein Saver 903 cards (Whatman, Maidstone, UK)
and dried for 3–4h at ambient temperature (AT) in a hori-
zontal position on the bench to produce dried plasma spots
(DPS). The cards were then placed in zip-lock plastic bags
(Whatman, Maidstone, UK) containing a desiccant and
maintained at 4°C up to 8 months.
After this period, a biopsy punch (Integra Miltex, NY,
USA) was used to cut out two discs from the cards of each
patient. The discs were placed in the 96-well plate and 70μl
of the elution buffer (2% BSA, 0.1% Tween-20 in PBS 1X)
was added. The plate was incubated at ambient temperature
for 1 hour in a shaker to elute all cytokines and chemokines
of plasma deposited on filter paper.
2.7. Cytometric Bead Array (CBA) Assay. Levels of IFN-γ,
TNF-α, IP-10, IL-2, IL-10, MIG, and MCP-1 were quantified
in frozen plasma and DPS-elucidated sample from control
and SLA-stimulated and PHA-stimulated whole blood using
the BD Cytometric Bead Array Human Flex Set (Becton
Dickinson Biosciences, USA) following the manufacturer’s
instructions. Briefly, 50μl of the plasma of each patient was
incubated for 1 h at ambient temperature with 50μl of cap-
ture beads. After incubation, 50μl of the detection antibody
was added and the mixture was placed 2 hours at ambient
temperature. Data were acquired using a FACSCalibur flow
cytometer and analysed using the Flow Cytometric Analysis
Program Array (BD Biosciences, USA) by manual clustering.
Cytokines and chemokine concentrations (expressed in
pg/ml) produced in response to SLA or PHA stimulation
were determined by subtracting background levels measured
in the negative control samples (nonstimulated tube).
2.8. Data Analysis. Data analysis was performed with
GraphPad Prism v6.0 software (GraphPad Software, USA).
Continuous data was presented as the median with inter-
quartile ranges (IQR) and the normality of data was checked
by the Shapiro-Wilk test. The concentrations of analytes
before and after treatment were compared using the non-
parametric Wilcoxon signed-rank test. The cut-off values
for each cytokine and chemokine shown in Figures 1 and 2
were determined by calculating the optimal point in the
receiver operating characteristic (ROC) curves for discrimi-
nating active disease from cured status. Spearman correlation
coefficients were calculated between baseline parasite load
and cytokine/chemokine concentrations or L. infantum-
and L. donovani-stimulated cytokine levels. A p value ≤
0.05 was considered as statistically significant.
3. Results
3.1. Sociodemographic and Clinical Characteristics of VL
Patients. A total of 13 confirmed primary VL cases were
included. All the patients were male with a median age of
22 years and only five (38.4%) were literate. Almost all
(92.31%) were migrant workers, functioning as farmers or
daily labourers (see Table 1). Related to their clinical condi-
tion, the median body mass index (BMI) was 16.4 kg/m2,
classifying 12 (92.3%) patients as being underweight. Other
pathologies were diagnosed in three (23.1%) patients, such
as pneumonia (n = 1), malaria (n = 1), and giardia (n = 1).
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Regarding the treatment of leishmaniasis, 10 (76.9%) of them
were treated with a combination treatment of paromomycin
(PM) and sodium stibogluconate (SSG) while three patients
(38.5%) were treated with AmBisome monotherapy. All
patients were successfully treated and discharged.
3.2. IFN-γ, TNF-α, and IP-10 in SLA-Stimulated Plasma as
Potential Biomarkers for Treatment Efficacy Monitoring in
VL Patients. The cytokine/chemokine concentrations were
measured in the soluble L. donovani antigen-stimulated
plasma of VL patients at time of diagnosis (D0), during treat-
ment (W1), and at the end of treatment (EOT) (Figure 1).
The levels of IFN-γ, TNF-α, and IP-10 increased significantly
after one week of treatment (median ðIQR ; p valueÞ =
























































































Figure 1: IFN-γ (a), TNF-α (b), IP-10 (c), IL-2 (d), and IL-10 (e) levels in soluble L. donovani antigen-stimulated plasma of 13 VL patients at
active disease (D0), after one week of treatment (W1), and at the end of treatment (EOT). Each line curve represents an individual during
follow-up. Comparison of medians was made using the Wilcoxon paired t-test. ∗p < 0:05; ∗∗p < 0:01; ∗∗∗p < 0:001. Dotted line represents
the best cut-off for each cytokine/chemokine based on ROC analyses to discriminate active from cured status.
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95.61; <0.01); and 667.90 pg/ml (533.80-1601; 0.01), respec-
tively) compared to a baseline levels (D0) (median ðIQRÞ =
19:96 pg/ml (9.62–79.85); 6.56 pg/ml (3.86–43.25); and
149.40 pg/ml (68.01-440.90), respectively). The levels of these
cytokines/chemokines also presented a significant increase at
the end of treatment with a dose-response like relationship
(median (IQR; p value) = IFN-γ: 331.7 pg/ml (167.80-
950.80; <0.01); TNF-α: 150.60 pg/ml (40.68-489.30; <0.01);
and IP-10: 1979 pg/ml (863.30-2603; <0.01)) (Figures 1(a)–

























































































Figure 2: IFN-γ (a), TNF-α (b), IP-10 (c), IL-2 (d), and IL-10 (e) levels in soluble L. infantum antigen-stimulated plasma of 13 VL patients at
the active moment (D0), during one week of treatment (W1), and the end of treatment (EOT). Each line curve represents an individual during
follow-up. Comparison of medians was made using the Wilcoxon paired t-test. ∗p < 0:05; ∗∗p < 0:01; ∗∗∗p < 0:001. Dotted lines represent the
best cut-off for each cytokine/chemokine based on ROC analyses to discriminate the active from cured status.
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increased at W1 (median ðIQR ; p valueÞ = 0:1 pg/ml (0.10-
4.16; <0.5)), but significantly increased at EOT (median
(IQR; p value) = 1.24 pg/ml (0.10-71.57; <0.05)), compared
to D0 (0.1 pg/ml) (Figure 1(d)). IL-10 did not show signifi-
cant differences between the different time points
(Figure 1(e)). MCP-1 and MIG concentrations were lacking
a defined pattern across the different time points of the
study (data not shown).
To assess the specificity against the L. donovani strain
used in the assay, we performed a simultaneous stimulation
with the soluble L. infantum antigen. We found that the
stimulation with SLA from L. infantum showed the same
pattern of cytokine and chemokine production than stimula-
tion with SLA from L. donovani (Figure 2). The results show
a significant increase in IFN-γ, TNF-α, and IP-10 after one
week of treatment (W1, median ðIQR ; p valueÞ = 108:9 pg/ml
(41.34-194.50; <0.001); 74.38pg/ml (30.81-111.70; <0.001);
and 552.10pg/ml (306.00-1659; <0.05)) compared to base-
line levels (D0) of IFN-γ, TNF-α, and IP-10 (median
(IQR)=28.64pg/ml (12.15-70.48); 9.38pg/ml (4.54-39.40);
and 84.81pg/ml (0.10-399.50), respectively). The levels of
these cytokines/chemokines also presented a significant
increase at the end of treatment compared to D0 (EOT,
median ðIQR ; p valueÞ = IFN − γ : 361:20 pg/ml (108.20-1221;
<0.001); TNF-α: 247.50 pg/ml (80.12-908.60; <0.001); and
IP-10: 1284pg/ml (651.00-2646; <0.001)) (Figures 2(a)–2(c)).
IL-2, IL-10, MIG, and MCP-1 also showed very similar
patterns as previously described using the L. donovani
antigen (Figures 2(d)–2(e)). Moreover, excellent correlation
scores were observed for IFN-γ (r = 0:97; p < 0:001), TNF-α
(r = 0:95; p < 0:001), and IP-10 (r = 0:97; p < 0:001) levels
with L. infantum and L. donovani antigen stimulation. We
also observed good correlations for IL-2 (r = 0:78; p < 0:001),
IL-10 (r = 0:84; p < 0:001), MIG (r = 0:86; p < 0:001), and
MCP-1 (r = 0:74; p < 0:001) levels with L. infantum and
L. donovani antigen stimulation.
Comparative results were also obtained in response to the
general T cell mitogen PHA, which showed a low production
of cytokines and chemokines before treatment that increased
during treatment (see in Table S1 in Supplementary Material).
This indicated a good cell viability and immunocompetence
after cell activation for all samples, but also confirmed the
overall hyporesponsiveness observed during active VL
disease and its restoration upon successful treatment.
3.3. IFN-γ Showed the Highest Fold Increase after SLA
Stimulation Plasma at the End of Treatment. The fold change
in each cytokine/chemokine concentration after one week of
treatment (W1) and at the end of the treatment (EOT), in
relation to their concentration at the time of active disease
(D0), is shown in Figure 3. The concentration of IFN-γ
(p < 0:001) in the SLA-stimulated plasma increased 3.8 times
after one week of treatment, while TNF-α (p = 0:001) and
IP-10 (p = 0:013) increased around fivefold (Figure 3). At
the end of the treatment, the concentrations of IFN-γ
(p < 0:001), TNF-α (p < 0:001), and IP-10 (p < 0:001)
increased significantly by 13.1, 10.8, and 9.9 times, respec-
tively. IL-2 levels were also increased 1.3 times from D0 to
EOT in a statistically significant manner (p = 0:023). In
addition, we found very similar fold changes using the soluble
L. infantum antigen as specific stimulation (see Figure S1 in
Supplementary Material).
Without exception, all 13 patients experienced a steep
and incremental increase during treatment in IFN-γ and
TNF-α levels towards successful disease recovery, arguing
to investigate its prognostic value in larger cohorts including
treatment failures as a potential pretest-posttest.
3.4. IFN-γ Levels Showed Highest Discriminatory Power to
Determine a Cured Status in VL Patients at End of
Treatment. To investigate the possibility of a general,
single-time point-based test instead of a pre-post treatment
evaluation, we calculated the optimal cut-off values to deter-
mine a cured (EOT) status by means of ROC analyses. For
IFN-γ, TNF-α, IP-10, IL-2, and IL-10 with L. donovani stim-
ulation, the optimal cut-off values were 48.13 pg/ml,
25.35 pg/ml, 452.90 pg/ml, 20.02 pg/ml, and 37.29 pg/ml,
respectively (depicted as dotted lines in Figures 1 and 2).
Table 2 shows the proportion of patients that produced levels
above the respective cut-off values after SLA stimulation.
Results showed that active VL patients recovered their ability
to mount a specific cellular immune response against
Table 1: Sociodemographic and clinical characteristics of study





Male gender, n (%) 13 (100)
Age (years), median (min–max) 22 (17-27)
Occupation, n (%)
Farmer 6 (46.1)
Daily labourer 7 (53.9)
Literacy, n (%) 5 (38.4)
Marital status, n (%)
Single 12 (92.3)
Married 1 (7.7)
Migrant worker, n (%) 12 (92.3)
Clinical characteristics
BMI, median (kg/m2) (min–max) 16.4 (13.6-18.4)
Fever, n (%) 9 (69.2)
Conjunctival pallor, n (%) 12 (92.3)
Edema, n (%) 6 (46.2)
Other pathology, n (%) 3 (23.1)
Palpable spleen size (cm),











min: minimum; max: maximum; n: total number; SD: standard deviation;
PM: paromomycin; SSG: sodium stibogluconate.
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Leishmania during the treatment period, producing IFN-γ,
TNF-α, IP-10, and IL-2 (with the exception of IL-10).
IFN-γ, TNF-α, and IP-10 seemed to be the most promising
biomarkers after one week of treatment. At end of treatment,
a production of IFN-γ and IP-10 above the cut-off was able
to identify 100% and 92% of the cured patients, arguing for fur-
ther research towards a universal cut-off value to define cure.
Yet, 3-4 VL patients did produce cytokine levels above the
cut-off value at D0 (see Table 2), arguing for further optimiza-
tion towards a universal cut-off value to define cure. These 4
patients all showed a median increase of 5.0, 1.7, and 7.6 times
at EOT for IFN-γ, TNF-α, and IP-10, respectively.
3.5. IFN-γ and IP-10 Are Stable Markers in Filter Paper. After
elution of the SLA-stimulated plasma (L. donovani or L.
infantum antigen) from the filter paper (DPS) that was stored
at 4 °C for a median of 225 (IQR: 106-266) days and shipped
at ambient temperature, we found that IFN-γ and IP-10 were
the most stable analytes (Figure 4). It is important to high-
light that the levels of TNF-α, IL-2, and IL-10 after elution
of filter paper were below the detection limit of the technique,
and that MIG and MCP-1 values after elution of the filter
paper were also on the low side and, in comparison with
frozen plasma, lacking a defined pattern across the differ-
ent time points of the study. Compared to the frozen
plasma method, concentrations were around 1/10 lower,
indicating a significant loss of material due to the nature
of the preservation method, as previously described [24].
Nevertheless, we could still observe similar patterns and
IFN-γ and IP-10 levels significantly increased after one
week of treatment with soluble L. donovani stimulation
(median ðIQR ; p valueÞ = 11:22 pg/ml (5.10-20.68; 0.0327)
and 57.23 pg/ml (34.47-144.50; 0.1909), respectively) com-
pared to baseline levels (D0). The levels of these cytoki-
nes/chemokines also presented a statistically significant
increase at the end of treatment compared to D0 (median
ðIRQ ; p valueÞ = 58:37 pg/ml (42.7-141.9; 0.0002) and
501.4 pg/ml (156.50-855; 0.0002), respectively) (Figure 4(a)).
With L. infantum stimulation, we observed similar differ-
ences (Figure 4(b)). These findings indicate the stability of
the patterns of the IFN-γ and IP-10 in a more field-adapted
preservation method and robustness of the findings.
3.6. IP-10, TNF-α, and IFN-γ Concentrations Showed
Significant Correlation with the Parasite Load at Baseline.
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Figure 3: Fold changes in cytokine/chemokine concentrations during treatment of 13 VL patients, measured in soluble L. donovani antigen-
stimulated plasma. Fold increase during W1 and EOT compared to D0 was calculated by dividing the value of (W1, EOT) by D0 values.
p values are represented for comparison with baseline concentration at the time of diagnosis (D0). ∗p < 0:05; ∗∗p < 0:01; ∗∗∗p < 0:001.
Table 2: Proportion of patients that produced levels above the calculated optimal cut-off values after SLA stimulation of a whole blood
sample.
Analytes (cut-off value)













IFN-γ (48.1 pg/ml) 4/13 (31) 10/13 (77) 13/13 (100) 4/13 (31) 10/13 (77) 13/13 (100)
TNF-α (25.4 pg/ml) 4/13 (31) 9/13 (69) 10/13 (77) 4/13 (31) 10/13 (77) 11/13 (85)
IP-10 (452.9 pg/ml) 3/13 (23) 11/13 (85) 12/13 (92) 3/13 (23) 9/13 (69) 12/13 (92)
IL-2 (20.0 pg/ml) 0/13 (0) 0/13 (0) 5/13 (38) 0/13 (0) 0/13 (0) 5/13 (38)
IL-10 (37.3 pg/ml) 5/13 (38) 5/13 (38) 4/13 (31) 3/13 (23) 5/13 (38) 5/13 (38)
D0: active moment, day zero; W1: first week of the treatment; EOT: end of treatment; N : number of patients; %: percentage of positives patients that produce
cytokines/chemokines.
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stimulated blood are reflecting parasite reduction in the
spleen, we studied the correlation between spleen baseline
parasite load and SLA-stimulated responses in whole blood.
Of all cytokines tested, an inverse correlation between
the baseline concentration of IFN-γ (r = −0:74, p < 0:001),
TNF-α (r = −0:52, p = 0:022), or IP-10 (r = −0:56, p = 0:012)
and the baseline parasite load could be observed (Figure 5).
This inverse relationship suggests that a recovery in cytokine/-
chemokine production after SLA stimulation could be used as
a proxy for parasite reduction at end of treatment.
4. Discussion
In this small but unique cohort study of primary VL cases,
13 Ethiopian patients with successful treatment all showed
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Figure 4: Levels of IFN-γ and IP-10 eluted from dried plasma spots (DPS) stored at 4°C for a median of 255 days in VL patients at D0, W1,
and EOT. Blood was stimulated with lyophilized (a) L. donovani antigen or (b) L. infantum antigen. Each line curve represents one individual.




























































Figure 5: Correlation of baseline parasite load with IFN-γ (a), TNF-α (b), and IP-10 (c) levels after SLA L. donovani stimulation at D0.
Correlation between analyte concentrations with parasitic load was based on all active VL cases of which baseline data was available
(n = 19), by means of the nonparametric Spearman test.
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production upon in vitro stimulation with soluble Leish-
mania antigens during treatment. This reflected a detect-
able restoration of the profound immunosuppression
previously reported in active VL patients [30]. Despite
being in contrast with a previous cross-sectional study in
India where no statistically significant differences were
found after quantification of IFN-γ levels between active
and cured VL patients [31], our results consolidated the
findings of the sole East African report. The latter reported
on an incremental increase in IFN-γ levels in cured individ-
uals living in Northwest Ethiopia as compared to active
patients but could not detect differences in IL-10 levels.
Similar findings were reported in Turkish, Indian, Iranian,
Spanish, and Bangladeshi VL patients [20, 21, 23, 32, 33],
indicating a typical cellular hyporesponsiveness during
active disease that restores after successful therapy, as was
also reported in studies using peripheral blood mononu-
clear cell (PBMC). This was also reflected in the gradual
increase in nonspecific PHA stimulation which suggests a
broad mechanism of immunosuppression that merits further
investigation. Studies in Spain and Ethiopia demonstrated
that a long-lasting memory response remains in cured
patients and increased levels of IFN-γ and IFN-γ-inducible
protein 10 (IP-10) could be detected in almost all patients
at 6 and 12 months after treatment [21, 23]. This is, however,
the first time that a longitudinal study in diseased individuals
was performed with an early measurement at one week of
treatment. It showed an early almost dose-response-like rate
of recovery with 9 to 13-fold increases in IFN-γ, IP-10, or
TNF-α levels after therapy (EOT).
Due to the sharp 13-fold increase in IFN-γ levels during
treatment, it was almost possible to perfectly discriminate
between diseased (D0) and cured (EOT) status. Although
we did not have splenic parasite counts at end of treatment,
the levels of IFN-γ, IP-10, or TNF-α seemed to be inversely
associated with the parasite load at baseline and therefore
could reflect parasite clearance. This further argues for the
development and validation of this assay as an alternative test
of cure in larger cohort studies including treatment failure
cases to establish its prognostic and diagnostic value in early
to late stages of the treatment.
Because IFN-γ is produced in rather low quantities, other
IFN-γ-associated cytokines and chemokines have been pro-
posed to show better performance. The production of IP-10
has a role in the host response to VL by initiation of early
immune responses and further increasing the production of
IFN-γ, which indirectly promotes killing of the intracellular
parasite [34]. In our study, plasma concentrations of IP-10
after SLA stimulation were also significantly increased during
successful treatment, but not as robustly in all individual
patients as IFN-γ or TNF-α. A previous study also showed
IP-10 as an accurate global marker of infection and cure
[21]. We found similar results for TNF-α levels during
treatment. TNF-α has an indirect role for parasite
clearance by stimulating the production of IFN-γ. Previously,
a significantly elevated production of TNF-α was also
observed in VL-cured solid organ transplant subjects and
VL-cured individuals from Spain after 6 months of
treatment [20, 35].
Even though Th1 cell-mediated immunity for parasite
control is associated with production of IL-2 by activated T
cells [16], it was produced at much lower concentration
and there was no significant production of IL-2 during treat-
ment but only at the end of treatment. In previous studies, its
concentration was also below detection limit during active
infection while cured individuals were able to produce a sig-
nificant concentration of this cytokine [20, 21]. This suggests
that production of IL-2 is rather a late signature of cure.
High levels of the anti-inflammatory cytokine IL-10 have
been associated with the depressed cell-mediated immunity
(CMI) during active VL, and PBMC-based assays have
showed elevated production of this cytokine during active
infections that decreased over time [20, 36]. Nevertheless, we
observed no changes in IL-10 levels during treatment which
was also reported by Adem et al. in a very similar patient
population [23]. These challenge the common dogma in
PBMC assays or point towards other sources of IL-10. In a
similar manner, our findings showed no specific pattern for
MIG levels during treatment with SLA or PHA stimulation,
although a previous study in Spain reported MIG to be a good
biomarker of cure in L. infantum-infected individuals [21].
A similar whole blood interferon-γ release assay is being
used in tuberculosis patients to identify specific immunity
during latent infection (commercialized as QuantiFERON®)
[37]. The Leishmania-specific whole blood stimulation assay
has also been evaluated in different endemic areas of Leish-
mania spp. for the detection of subjects with asymptomatic
infection [36, 38, 39]. However, specificity problems of the
soluble Leishmania antigens used, in particular cross-
reactivity with similar pathogens like Trypanosoma cruzi
and Toxoplasma gondii, could be problematic when targeting
a diagnostic or predictive tool in coendemic countries, which
may be of lesser concern for its development as a test-of-cure.
Field applicability is also important when testing for
asymptomatic infection in the rural settings of endemic
areas. We found comparable patterns in cytokine/chemokine
expressions of frozen plasma and dried plasma spots that
were stored at 4°C for up to 8 months and shipped at ambient
temperature. Similar results were also obtained on negative
control subjects and asymptomatic individuals from Spain
and Bangladesh, where the samples stored for 10 days at
ambient temperature or -20°C [24]. This indicates that an
adapted version of the WBA with dry stimulated plasma
spots instead of frozen supernatants could be developed for
the rural less-equipped health centers, thereby avoiding a
cold-chain transport and decreasing the cost of transport
to reference centers. Despite a loss in quantity, the ratio
between D0 and EOT remained identical by which a
pretest-posttest would be advised. In addition, no significant
differences in cytokine/chemokine expressions between SLA
from L. infantum and SLA from L. donovani stimulation were
observed. Similar results were reported in studies determining
the CMI at endemic areas for L. infantum and L. donovani
[21]. This suggests that many immunodominant antigens
are shared across the species and a global assay could be
developed [40].
Despite a number of inherent and important limitations
such as the lack of treatment failure cases, low number of
9Journal of Immunology Research
individuals, and lack of long-term follow-up after treatment
stop, we believe these findings can spur and steer larger
cohort studies to evaluate its diagnostic and prognostic value
as a treatment monitoring tool.
5. Conclusion
This pilot study indicated a detectable restoration of cell-
mediated immunity against VL that could be used to follow
up treatment efficacy and enable better patient management.
This longitudinal pilot study showed that IFN-γ had a steady
and on average 13-fold increase from time of diagnosis until
end of treatment in successfully treated VL patients and
would be the recommended analyte out of a panel of 7 previ-
ously proposed markers to be prioritized. We hope the rec-
ommendations in this work on the use of WBA in
combination with filter paper will facilitate treatment moni-
toring studies of more VL patients in the search for an alterna-
tive less-invasive test-of-cure. In particular, an early marker of
treatment efficacy would be highly warranted to limit the
duration or steer the chemotherapeutic choice of treatment.
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